Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now.
On June 12, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts for the current outbreak of Ebola Bundibugyo virus disease. Anu Osinusi, Vice President of Clinical Development, Virology at Gilead Sciences, said the company recognizes the urgency of global health emergencies and is working with partners to support the outbreak response.
On June 8, 2026, Merck (MRK) and Gilead Sciences, Inc. (NASDAQ:GILD) announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 study evaluating Trodelvy in combination with KEYTRUDA, compared with KEYTRUDA monotherapy, in certain patients with previously untreated metastatic non-small cell lung cancer whose tumors expressed PD-L1. The decision followed a recommendation from the external Data Monitoring Committee after its review of the pre-specified final analysis of progression-free survival and interim analysis of overall survival. The companies said a numerical improvement in progression-free survival was observed, but did not reach statistical significance, while the probability of achieving statistically significant overall survival at the planned final analysis was unlikely.
On June 2, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced Phase 3 results in primary biliary cholangitis showing that Livdelzi led to significantly more patients achieving normalization of alkaline phosphatase, or ALP, compared with placebo after 52 weeks. The primary endpoint was defined as ALP less than or equal to 1.0 upper limit of normal and a greater than or equal to 15% decrease from baseline. Cynthia Levy of the University of Miami Miller School of Medicine said the IDEAL results further support the efficacy and safety profile of Livdelzi and extend its evidence base to a broader population of people living with PBC.
Gilead Sciences, Inc. (NASDAQ:GILD) discovers, develops, and commercializes medicines in areas of unmet medical need in the United States, Europe, and internationally.
While we acknowledge the risk and potential of GILD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GILD and that has 10,000% upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
